Effects of one-year treatment with canagliflozin or sitagliptin on glycaemic control and beta cell function measures in subjects with type 2 diabetes on metformin plus sulfonylurea

被引：0
|
作者：
Schernthaner, G. [1 ]
Ferrannini, E. [2 ]
Mari, A. [3 ]
Tong, C. [4 ]
Kawaguchi, M. [4 ]
Meininger, G. [4 ]
Polidori, D. [4 ]
机构：
[1] Rudolfstiftung Hosp Vienna, Vienna, Austria
[2] Univ Pisa, Sch Med, I-56100 Pisa, Italy
[3] CNR, Inst Biomed Engn, Padua, Italy
[4] Janssen R&D LLC, Raritan, NJ USA
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
993
引用
收藏
页码：S398 / S399
页数：2
相关论文
共 50 条
  • [1] One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    Hanefeld, M
    Brunetti, P
    Schernthaner, GH
    Matthews, DR
    Charbonnel, BH
    DIABETES CARE, 2004, 27 (01) : 141 - 147
  • [2] Achievement of weight loss with canagliflozin, sitagliptin and glimepiride in combination with metformin or metformin plus sulfonylurea in patients with Type 2 diabetes
    Stein, L.
    Thompson, G.
    Diels, J.
    Thilakarathne, P.
    Girod, I.
    DIABETIC MEDICINE, 2014, 31 : 145 - 145
  • [3] One year treatment with exenatide improves β cell function and glycaemic control in metformin treated type 2 diabetes patients
    Bunck, M. C.
    Diamant, M.
    Corner, A.
    Eliasson, B.
    Malloy, J. L.
    Shaginian, R. M.
    Deng, W.
    Kendall, D. M.
    Taskinen, M.-R.
    Smith, U.
    Yki-Jarvinen, H.
    Heine, R. J.
    DIABETOLOGIA, 2007, 50 : S111 - S112
  • [4] Canagliflozin Treatment Improves Beta Cell Function in Subjects with Type 2 Diabetes
    Polidori, David
    Zhao, Yue
    Sha, Sue
    Canovatchel, William
    DIABETES, 2010, 59 : A176 - A176
  • [5] One-year effects of liraglutide on pancreatic beta cell function and glycaemic control in Japanese type 1 diabetes with residual insulin secretion
    Hamamoto, Y.
    Mori, K.
    Honjo, S.
    Kawasaki, Y.
    Fujimoto, K.
    Tatsuoka, H.
    Matsuoka, A.
    Wada, Y.
    Ikeda, H.
    Koshiyama, H.
    DIABETOLOGIA, 2012, 55 : S300 - S300
  • [6] Effects of exenatide plus rosiglitazone on measures of beta cell function and insulin sensitivity in subjects with type 2 diabetes previously treated with metformin
    Glass, L. C.
    Triplitt, C.
    Lewis, M. S.
    Qu, Y.
    Guo, Y.
    Maggs, D.
    DeFronzo, R. A.
    DIABETOLOGIA, 2009, 52 : S286 - S286
  • [7] Effects of Exenatide Plus Rosiglitazone on Beta Cell Function and Insulin Sensitivity in Subjects with Type 2 Diabetes on Metformin
    Defronzo, Ralph A.
    Triplitt, Curtis
    Qu, Yongming
    Lewis, Michelle S.
    Gray, Alison
    Maggs, David
    Glass, Leonard C.
    DIABETES, 2009, 58 : A133 - A134
  • [8] Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin
    Rosenstock, J.
    Polidori, D.
    Zhao, Y.
    Sha, S.
    Arbit, D.
    Usiskin, K.
    Capuano, G.
    Canovatchel, W.
    DIABETOLOGIA, 2010, 53
  • [9] Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes
    Qi, D. S.
    Teng, R.
    Jiang, M.
    Davies, M. J.
    Kaufman, K. D.
    Amatruda, J. M.
    Williams-Herman, D.
    DIABETOLOGIA, 2008, 51 : S36 - S36
  • [10] Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
    Schernthaner, Guntram
    Gross, Jorge L.
    Rosenstock, Julio
    Guarisco, Michael
    Fu, Min
    Yee, Jacqueline
    Kawaguchi, Masato
    Canovatchel, William
    Meininger, Gary
    DIABETES CARE, 2013, 36 (09) : 2508 - 2515
12345